Investment Analysts’ Weekly Ratings Changes for Madrigal Pharmaceuticals (MDGL)

Several analysts have recently updated their ratings and price targets for Madrigal Pharmaceuticals (NASDAQ: MDGL):

• 9/24/2026 – Madrigal Pharmaceuticals is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $704.00 price target on the stock.
• 9/24/2026 – Madrigal Pharmaceuticals is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $704.00 price target on the stock.
• 9/23/2026 – Madrigal Pharmaceuticals is now covered by Citigroup Inc.. They set a “buy” rating and a $725.00 price target on the stock.
• 9/23/2026 – Madrigal Pharmaceuticals is now covered by Citigroup Inc.. They set a “buy” rating and a $725.00 price target on the stock.
• 8/4/2026 – Madrigal Pharmaceuticals was upgraded by Wolfe Research from “peer perform” to “outperform”. They now have a $605.00 price target on the stock.
• 8/3/2026 – Madrigal Pharmaceuticals had its price target lowered by Barclays PLC from $964.00 to $962.00. They now have an “overweight” rating on the stock.

Insider Transactions at Madrigal Pharmaceuticals

In related news, General Counsel Shannon Kelley sold 664 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $514.97, for a total value of $341,940.08. Following the sale, the general counsel directly owned 11,474 shares of the company’s stock, valued at $5,908,765.78. This trade represents a 5.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Sibold sold 5,221 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $542.39, for a total transaction of $2,831,818.19. Following the sale, the chief executive officer owned 197,746 shares of the company’s stock, valued at approximately $107,255,452.94. The trade was a 2.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 12,247 shares of company stock valued at $6,581,182. Corporate insiders own 17.60% of the company’s stock.

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for chronic liver diseases. The company’s primary focus is metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease that can lead to significant liver fibrosis, cirrhosis and other complications.

Madrigal’s lead product, Rezdiffra (resmetirom), is an oral thyroid hormone receptor beta agonist. In 2024, the U.S. Food and Drug Administration approved Rezdiffra for use with diet and exercise to treat adults with noncirrhotic MASH accompanied by moderate to advanced liver fibrosis.